Apo-sucralfate

Category

Apo-sucralfate




Useful info

Apo-sucralfate Brand names, Apo-sucralfate Analogs

Apo-sucralfate Brand Names Mixture

  • No information avaliable

    • Apo-sucralfate Chemical_Formula

    C13H10N2O4

    Apo-sucralfate RX_link

    http://www.rxlist.com/cgi/generic2/thalidom.htm

    Apo-sucralfate fda sheet

    Apo-sucralfate FDA

    Apo-sucralfate msds (material safety sheet)

    Apo-sucralfate MSDS

    Apo-sucralfate Synthesis Reference

    No information avaliable

    Apo-sucralfate Molecular Weight

    258.23 g/mol

    Apo-sucralfate Melting Point

    270 oC

    Apo-sucralfate H2O Solubility

    545 mg/L

    Apo-sucralfate State

    Solid

    Apo-sucralfate LogP

    -0.146

    Apo-sucralfate Dosage Forms

    Tablets for oral administration (50 mg); Capsules for oral administration (50 mg, 100 mg and 200 mg)

    Apo-sucralfate Indication

    For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

    Apo-sucralfate Pharmacology

    Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.

    Apo-sucralfate Absorption

    The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.

    Apo-sucralfate Toxicity

    The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.

    Apo-sucralfate Patient Information

    Apo-sucralfate Organisms Affected

    Humans and other mammals